Title:
HUMANIZED SINGLE-CHAIN ANTIBODY AGAINST COMPLEMENT C3 MOLECULE AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/159946
Kind Code:
A1
Abstract:
Provided is a humanized single-chain antibody against a complement C3 molecule; the light chain and heavy chain of the antibody have CDR regions, and the equilibrium dissociation constant KD(m) reaches 2.06×10-11. In the treatment of MRL/lpr lupus erythematosus mice, the described single-chain antibody can improve the survival rate of the mice. In addition, symptoms such as proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent/necrosis in the treatment group are improved. The single-chain antibody can be used to prepare therapeutic drugs for autoimmune diseases.
Inventors:
TANG XIAOMIN (CN)
DU LANYING (CN)
DU LANYING (CN)
Application Number:
PCT/CN2021/073419
Publication Date:
August 19, 2021
Filing Date:
January 22, 2021
Export Citation:
Assignee:
BEIJING COMPLEMENT THERAPEUTICS LTD (CN)
International Classes:
C07K16/18; A61K39/395; A61P19/02; A61P29/00; A61P37/02; C12N5/10; C12N15/13; C12N15/85
Foreign References:
| CN109575132A | 2019-04-05 | |||
| CN108752473A | 2018-11-06 | |||
| CN111171148A | 2020-05-19 | |||
| CN110922480A | 2020-03-27 | |||
| CN111171147A | 2020-05-19 | |||
| CN111234016A | 2020-06-05 |
Attorney, Agent or Firm:
BEIJING ZHONGTIAN LAWFIRM (CN)
Download PDF:
Previous Patent: LAMP HOLDER AND LAMP SYSTEM
Next Patent: CONTINUOUS VARIABLE QUANTUM KEY DISTRIBUTION METHOD AND SYSTEM
Next Patent: CONTINUOUS VARIABLE QUANTUM KEY DISTRIBUTION METHOD AND SYSTEM